Literature DB >> 22652233

microRNAs in cancer management.

Yi W Kong1, David Ferland-McCollough, Thomas J Jackson, Martin Bushell.   

Abstract

Since the identification of microRNAs (miRNAs) in 1993, and the subsequent discovery of their highly conserved nature in 2000, the amount of research into their function--particularly how they contribute to malignancy--has greatly increased. This class of small RNA molecules control gene expression and provide a previously unknown control mechanism for protein synthesis. As such, it is unsurprising that miRNAs are now known to play an essential part in malignancy, functioning as tumour suppressors and oncogenes. This Review summarises the present understanding of how miRNAs operate at the molecular level; how their dysregulation is a crucial part of tumour formation, maintenance, and metastasis; how they can be used as biomarkers for disease type and grade; and how miRNA-based treatments could be used for diverse types of malignancies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652233     DOI: 10.1016/S1470-2045(12)70073-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  330 in total

1.  An integrated approach of predicted miR-34a targets identifies a signature for gastric cancer.

Authors:  Tiantian Tang; Rongjian Su; Baoquan Wang; Yunli Zhang
Journal:  Oncol Lett       Date:  2015-05-26       Impact factor: 2.967

2.  Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma.

Authors:  Pingping Yan; Miaojuan Xia; Fei Gao; Guanxiu Tang; Hui Zeng; Shuo Yang; Hongmei Zhou; Dan Ding; Lina Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 3.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

4.  Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments.

Authors:  Nicole Guzman; Kitty Agarwal; Dilip Asthagiri; Lianbo Yu; Motoyasu Saji; Matthew D Ringel; Michael E Paulaitis
Journal:  Mol Cancer Res       Date:  2015-02-26       Impact factor: 5.852

Review 5.  Prospects of miRNA-based therapy for pancreatic cancer.

Authors:  Priya Pai; Satyanarayana Rachagani; Chandrakanth Are; Surinder K Batra
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 6.  MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer.

Authors:  Wei-xian Chen; Shan-liang Zhong; Ming-hua Ji; Meng Pan; Qing Hu; Meng-meng Lv; Zhou Luo; Jian-hua Zhao; Jin-hai Tang
Journal:  Tumour Biol       Date:  2013-11-22

7.  MiR-21 Suppresses Anoikis through Targeting PDCD4 and PTEN in Human Esophageal Adenocarcinoma.

Authors:  Meng-Ya Zhao; La-Mei Wang; Jing Liu; Xing Huang; Jing Liu; Ya-Fei Zhang
Journal:  Curr Med Sci       Date:  2018-04-30

8.  Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis.

Authors:  Sho Sugawara; Yasutaka Yamada; Takayuki Arai; Atsushi Okato; Tetsuya Idichi; Mayuko Kato; Keiichi Koshizuka; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2018-03-14       Impact factor: 3.172

Review 9.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

10.  MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of IκBα both in vitro and in vivo.

Authors:  Guang Yang; Dayong Han; Xin Chen; Daming Zhang; Lu Wang; Chen Shi; Weiguang Zhang; Chenguang Li; Xiaofeng Chen; Huailei Liu; Dongzhi Zhang; Jianhao Kang; Fei Peng; Ziyi Liu; Jiping Qi; Xin Gao; Jing Ai; Changbin Shi; Shiguang Zhao
Journal:  Neuro Oncol       Date:  2014-01-23       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.